The Effect of Parental Imprinting on the INS-IGF2 Locus of Korean Type I Diabetic Patients

Heung Sik Kim, M.D.*, Dong Wook Lee, M.D.*, Sang Jun Lee, M.D.*, Bo Hwa Choi, M.D.*, Sung Ik Chang, M.D.*, Hyun Dae Yoon, M.D.* and In Kyu Lee, M.D.*

Departments of Pediatrics*, Internal Medicine†, Anatomy‡
Keimyung University Dongsan Medical Center, Daegu, Korea; Department of Internal Medicine†, School of Medicine,
Catholic University of Daegu, Daegu, Korea

Background: Insulin-dependent diabetes mellitus (IDDM) is caused by the autoimmune destruction of pancreatic β-cells. Susceptibility to IDDM appears to depend on more than one genetic locus. Evidence of a genetic linkage for IDDM2 was found in male meioses from French and North American populations. It is linked to maternal imprinting (i.e., monoallelic expression of the insulin gene) that is considered the most likely cause of these gender-related differences. IGF2 is expressed only in the paternal allele and, therefore, is considered a candidate gene for IDDM2 transmission because of its important autocrine/paracrine effects on the thymus, lymphocytes and pancreas. Nevertheless, it remains controversial whether the parental origin of IDDM2 influences IDDM susceptibility.

Methods: Using PCR and semi-quantitative RT-PCR, we analyzed the INS/PstI+1127 and IGF2/Apal polymorphisms and RNA expression level between PstI (+/-) and PstI (+/+) to determine genotype and allele-specific expression of the INS and IGF2 genes.

Results: INS/PstI (+/+) and IGF2/Apal (+/-) were observed in 36 (97.3%) of 37 IDDM patients and in 29 (72.5%) of 40 IDDM patients, respectively. The presence of both IGF2 alleles in RNA was observed in 21 (91.6%) of 24 IDDM patients. Our results show a 3-fold increase in RNA expression from PstI (+/-) allele over PstI (+/+). allele.

Conclusion: Our conclusion does not entirely exclude IGF2 as the gene involved in IDDM2, even though the parental effect of IDDM2 transmission is not related to IGF2 maternal imprinting. The INS genotype appeared mostly in the PstI (+/+ ) homozygote and, therefore, we could not explain the INS imprinting pattern in Korean type 1 diabetic patients. Genetic differences between populations may account for the discrepancy between Korean type 1 diabetic patients and American or French type 1 diabetic patients.

Key Words: Genomic imprinting; Diabetes Mellitus; INS; IGF2; Korea

INTRODUCTION

Parental genomic imprinting is the phenomenon in which the differential behavior of a gene depends on the sex of the transmitting parent. Either an imbalance of parental chromosomes in the embryo or an aberrant imprinting of these genes is implicated in an increasing number of genetic disorders.

Type 1 diabetes mellitus is caused by the autoimmune destruction of pancreatic β-cells. It is a polygenic disorder, linked to several genetic loci and therefore, phenotype expression is influenced by a number of susceptibility genes as well as environmental factors.
Recent genome wide linkage studies indicate that genes in the HLA class II region provide the major genetic susceptibility to IDDM\(^{10}\). The insulin gene (INS) region on chromosome 11p15.5 (IDDM2) has also been shown to contribute to IDDM susceptibility in many populations\(^{11-13}\). The remaining genetic component is largely unknown, although recent studies have revealed the presence of several loci showing a significant genetic linkage\(^{14, 15}\). That one or more of these loci may be subject to parental imprinting was first suggested in the observation that IDDM is transmitted by diabetic fathers more than twice as often as by diabetic mothers\(^{16}\). Further, more direct evidence that IDDM transmission is modified by parental imprinting was generated by a large study of the IDDM locus in a French and mixed North American population\(^{16-19}\). But it is controversial whether IDDM transmission is positively associated with type 1 diabetes in Asians.

The IDDM2 locus was previously mapped to a 4.1-kb region spanning the insulin gene and a variable number of tandem repeats (VNTR) locus on the human chromosome 11p15.5\(^{20}\). Genetic susceptibility to IDDM is encoded by several loci, one of which (IDDM2) maps to a variable number of tandem repeats (VNTR) minisatellite, upstream of the insulin gene (INS). The short class I VNTR alleles (26-63 repeats) predispose to IDDM, while class III alleles (140-210 repeats) have a dominant protective effect\(^{21}\). Class III alleles are associated with marginally lower INS mRNA levels than class I in the human adult and fetal pancreas in vivo. Class I alleles are found with higher frequencies in type 1 diabetic patients than the class III alleles\(^{22, 23}\). The shorter alleles of class I predispose to IDDM, while the longer class III alleles are protective. These may be related to type 1 diabetes pathogenesis, as insulin is the only known cell-specific IDDM autoantigen. INS is a target of tissue-specific VNTR transcriptional effects and is the only known cell-specific autoantigen in type 1 diabetes\(^{24-27}\). Additionally, INS was recently shown to be imprinted in the yolk sac but not in the pancreas of mice\(^{28}\).

The IGFB2 gene is located immediately 3' to INS and is maternally imprinted in mice and in humans\(^{29, 30}\). This favors IGFB2 as the gene involved in IDDM transmission. However, in human peripheral lymphocytes, in which lectin stimulation induces IGFB2 transcription, imprinting is relaxed and the maternal copy is seen in most but not all individuals\(^{31, 32}\). The variable relaxation of imprinting may be the genotype-dependent trait postulated by Bain et al.\(^{33}\) which explains either the presence or absence of imprinting phenomena in different populations. Functionally, IGFB2 is also considered a candidate for the IDDM effect due to its well-characterized role as a mitogenic peptide with important autocrine/paracrine effects on the thymus, lymphocytes and pancreas\(^{34-36}\).

In this report, we studied patterns of IDDM2 parental transmission and the imprinting effects of the INS and IGF2 genes in Korean type 1 diabetic patients.

MATERIALS AND METHODS

**Samples** Whole blood samples were obtained from patients diagnosed with type 1 diabetes mellitus by the criteria of the National Diabetes Data Group. The samples used in the genotype and allele-specific expression analyses were obtained from 26 patients with no family history of diabetes and 16 patients with a family history of diabetes. The patients (aged 6-16) and their parents were recruited through the pediatric department of Dongsan hospital and the Diabetic Camp of the Daegu and Kyungbook.

**Nucleic Acid Preparation**

**Genomic DNA extraction.** Mononuclear cells were isolated from 10 mL of whole blood samples using ammonium chloride erythrocyte lysis buffer. Genomic DNA was purified using 100 µg/mL proteinase K and 0.5% sodium dodecyl sulfate and then extracted in phenoxochloromform/isooamylicohol (25:24:1).

**Total RNA extraction and cDNA synthesis.** Mononuclear cells were isolated from 10 mL of whole blood samples using Ficoll-Paque solution (Pharnacia Biotech., USA). Total cellular RNA was prepared as RNA mix using ammonium chloride in the extraction buffer. To generate cDNA, 2 µg total RNA was reverse-transcribed in 20 µL of reaction mixture containing 5 mmol MgCl\(_2\), 1 mmol dNTP, 1 U µL RNase inhibitor, 2.5 U µL reverse transcriptase and 2.5 M oligo d(T)\(_3\), for 1h at 42°C.

**Polymerase chain reaction (PCR).** A set of primers was generated to PCR-amplify a nucleotide segment, including the PstI or 127 restriction fragment length polymorphism (RFLP), in the 3' untranslated region of INS\(^{37}\). Sequences of the primer pair were as follows (5'-3'): INPsA, TGGTGGCAAGGCAGGCTGCA; INPsB, GTGTGTTCAAGGCTTTATT. Likewise, a primer set used to amplify IGFB2-exon 9, including an Apa I RFLP, was made as follows (5'-3'): IGFB2A, CCTGGACTTTGAGGGTTCAAGGGCTTTATT; IGFB2B, CCTGGACTTTGAGGGTTCAAGGGCTTTATT. 500 ng genomic DNA and 4 µL RT-product were subjected to PCR for 35 cycles in a mixture containing each primer pair exposed to the following conditions: for INS PCR,
The Effect of Parental Imprinting on the INS-IGF2 Locus of Korean Type I Diabetic Patients

RFLP Analysis. After PCR products were purified using the Wizard PCR Prep DNA purification system (Promega, USA), they were digested with 30 U of PstI or Apal at 37°C overnight and electrophoresed on 2% agarose gel or 6% polyacrylamide gel. The gel was then stained with ethidium bromide for visualization.

Expression studies. Expression of the INS and IGF2 genes was assessed using the same PCR primers. GAPDH served as an internal control for the reaction. A primer set to amplify GAPDH was made as follows (5'-3') : S, CGTCTTCACCACCATGGAGA; AS, CGGCCATCACGCCAAGTT. PCR amplification was carried out under the following conditions: initial denaturation at 95°C for 10 min by 35 cycles of 92°C for 1 min, 55°C for 1 min and 72°C for 2 min.

RFLP Analysis. After PCR products were purified using the Wizard PCR Prep DNA purification system (Promega, USA), they were digested with 30 U of PstI or Apal at 37°C overnight and electrophoresed on 2% agarose gel or 6% polyacrylamide gel. The gel was then stained with ethidium bromide for visualization.

**EXPERIMENTAL METHODS**

**Expression studies.** Expression of the INS and IGF2 genes was assessed using the same PCR primers. GAPDH served as an internal control for the reaction. A primer set to amplify GAPDH was made as follows (5'-3') : S, CGTCTTCACCACCATGGAGA; AS, CGGCCATCACGCCAAGTT. PCR amplification was carried out under the following conditions: initial denaturation at 95°C for 10 min by 35 cycles of 92°C for 1 min, 55°C for 1 min and 72°C for 2 min. RFLP Analysis. After PCR products were purified using the Wizard PCR Prep DNA purification system (Promega, USA), they were digested with 30 U of PstI or Apal at 37°C overnight and electrophoresed on 2% agarose gel or 6% polyacrylamide gel. The gel was then stained with ethidium bromide for visualization.

**RESULTS**

**Genotype Determination.** The families of type I diabetic patients were studied. Sixteen of 42 families were found to include type I diabetic members, and 3 of these diabetic patients had a diabetic mother. None of the patients had a diabetic father. A total of 42 type 1 diabetic patients were genotyped for the PstI and Apal polymorphism in INS and IGF2, respectively (Table 1). The absence of a restriction site in INS is indicated as the '+' allele, while the allele containing the cutting site is termed '-' allele. The absence and presence of the restriction site in IGF2 is indicated as the '-' and '+' allele, respectively. The INS PCR product was 191 bp long, although there was more than one PstI restriction site present (Figure 1). Digestion of the PCR products with PstI produced, in the presence of two restriction sites, fragments of size 86 bp and 61 bp. In the absence of restriction sites, a fragment of 147 bp was generated. The IGF2 PCR product was 236 bp long. Digestion of the PCR products with Apal, in the presence of a restriction site, produced a 173 bp fragment and, in the absence of restriction sites, a fragment of 236 bp was generated. PstI digestion of PCR products from genomic DNA demonstrated that 36 (97.3%) of the 37 IDDM patients tested were homozygous for the PstI (+/-) allele (Table 1, Figure 2A). PCR of genomic DNA revealed that 29 (72.5%) of the 40 type 1 diabetic patients were heterozygous (Apol (+/-)), while the others were homozygous (Apol (+/-)) for the Apal RFLP in IGF2 (Table 1). The frequencies of the INS/PstI (+/-) homozygous genotype were found to be much higher than the INS/PstI (+/-) heterozygous genotype. These results confirm that the INS/PstI (+/-) homozygote is the dominant genotype in Korean type I diabetic patients.

**Table 1. Genotype analysis for INS and IGF2 polymorphisms in IDDM**

| Alleles INS/PstI+1127 | total |
|-----------------------|-------|
| +/+                   | 36 (97.3%) |
| +/-                   | 1 (2.7%) |
| total                 | 37     |

| Alleles IGF2/Apal     | total |
|-----------------------|-------|
| -/-                   | 11 (27.5%) |
| +/-                   | 29 (72.5%) |
| total                 | 40     |

**Expression-specific expression of INS and IGF2.** We examined the presence of each allele in the RNA transcript from lymphocytes identified as heterozygous, PstI (+/-) and Apal (+/-). In Figure 2B and 2C, the amplification-digestion products of INS genomic and complementary DNA of two families are shown. One of the families expressed heterozygous and all were found to be both alleles for the PstI polymorphism in their genomic DNA (Figure 2C). In the other family, the mother was PstI (+/-) heterozygous and the patient was PstI (+/+). We could not demonstrate that the INS genotype was associated with parental imprinting in IDDM transmission because most of the patients had...
**PstI** (+/+) INS genotypes. As illustrated in Table 2, both IGF2 alleles resulted in *ApaI* digestion in 21 of the 24 *ApaI* (+/−) heterozygotes. In Figure 3B, a series of individuals are shown who exhibit biallelic IGF2 expression. Therefore, the presence of both of these alleles in RNA indicates that IGF2 imprinting is at least partially relaxed in these cells. The relative intensities of the *PstI* (+/−) and *PstI* (+/+) RNA transcripts were measured using semi-quantitative RT-PCR. We found a 3-fold higher level of RNA expression from the *PstI* (+/−) transcript compared to that of the *PstI* (+/+). We also measured the relative intensities of IGF2 RNA transcripts in the same type 1 diabetic patients. In this case, the expression of the *PstI* (+/−) transcript was greater than that of the *PstI* (+/+), although these patients showed biallelic IGF2 expression (Figure 4).

**Figure 2.** Allele-specific INS expression in IDDM patients. Genomic DNA (g) and cDNA (c) were amplified to detect an *PstI*-1127 polymorphism. A, INS monoallelic expression. B and C, PCR and RT-PCR analyses of allele usage in two families. m, marker; g, genomic DNA; c, complementary DNA

| IDDM | IGF2 | INS |
|------|------|------|
| CASE | gDNA | cDNA | F | M | gDNA | cDNA | F | M |
| ID1  | +/+  | +/+  | +/+ | +/− | +/− | +/− | +/− |
| ID2  | +/+  | +/+  | +/+ | +/− | +/− | +/− | +/− |
| ID3  | +/+  | +/+  | +/+ | +/− | +/− | +/− | +/− |
| ID4  | +/+  | +/+  | +/+ | +/− | +/− | +/− | +/− |
| ID5  | +/+  | +/+  | +/+ | +/− | +/− | +/− | +/− |
| ID6  | +/+  | +/+  | +/+ | +/− | +/− | +/− | +/− |
| ID7  | +/+  | +/+  | +/+ | +/− | +/− | +/− | +/− |
| ID8  | +/+  | +/+  | +/+ | +/− | +/− | +/− | +/− |
| ID9  | +/+  | +/+  | +/+ | +/− | +/− | +/− | +/− |
| ID10 | +/+  | +/+  | +/+ | +/− | +/− | +/− | +/− |
| ID11 | +/+  | +/+  | +/+ | +/− | +/− | +/− | +/− |
| ID12 | +/+  | +/+  | +/+ | +/− | +/− | +/− | +/− |
| ID13 | +/+  | +/+  | +/+ | +/− | +/− | +/− | +/− |
| ID14 | +/+  | +/+  | +/+ | +/− | +/− | +/− | +/− |
| ID15 | +/+  | +/+  | +/+ | +/− | +/− | +/− | +/− |
| ID16 | +/+  | +/+  | +/+ | +/− | +/− | +/− | +/− |
| ID17 | +/+  | +/+  | +/+ | +/− | +/− | +/− | +/− |
| ID18 | +/+  | +/+  | +/+ | +/− | +/− | +/− | +/− |
| ID19 | +/+  | +/+  | +/+ | +/− | +/− | +/− | +/− |
| ID20 | +/+  | +/+  | +/+ | +/− | +/− | +/− | +/− |
| ID21 | +/+  | +/+  | +/+ | +/− | +/− | +/− | +/− |
| ID22 | +/+  | +/+  | +/+ | +/− | +/− | +/− | +/− |
| ID23 | +/+  | +/+  | +/+ | +/− | +/− | +/− | +/− |
| ID24 | +/+  | +/+  | +/+ | +/− | +/− | +/− | +/− |
| ID25 | +/+  | +/+  | +/+ | +/− | +/− | +/− | +/− |
| ID26 | +/+  | +/+  | +/+ | +/− | +/− | +/− | +/− |
| ID27 | +/+  | +/+  | +/+ | +/− | +/− | +/− | +/− |
| ID28 | +/+  | +/+  | +/+ | +/− | +/− | +/− | +/− |
| ID29 | +/+  | +/+  | +/+ | +/− | +/− | +/− | +/− |
| ID30 | +/+  | +/+  | +/+ | +/− | +/− | +/− | +/− |
| ID31 | +/+  | +/+  | +/+ | +/− | +/− | +/− | +/− |
| ID32 | +/+  | +/+  | +/+ | +/− | +/− | +/− | +/− |
| ID33 | +/+  | +/+  | +/+ | +/− | +/− | +/− | +/− |
| ID34 | +/+  | +/+  | +/+ | +/− | +/− | +/− | +/− |
| ID35 | +/+  | +/+  | +/+ | +/− | +/− | +/− | +/− |
| ID36 | +/+  | +/+  | +/+ | +/− | +/− | +/− | +/− |
| ID37 | +/+  | +/+  | +/+ | +/− | +/− | +/− | +/− |
| ID38 | +/+  | +/+  | +/+ | +/− | +/− | +/− | +/− |
| ID39 | +/+  | +/+  | +/+ | +/− | +/− | +/− | +/− |
| ID40 | +/+  | +/+  | +/+ | +/− | +/− | +/− | +/− |
| ID41 | +/+  | +/+  | +/+ | +/− | +/− | +/− | +/− |
| ID42 | +/+  | +/+  | +/+ | +/− | +/− | +/− | +/− |

/+: heterozygote; +/+, −/−, homozygote; blank, unchecked g, genomic; c, complementary; F, father; M, mother

**Figure 3.** Representative examples of IGF2 expression from mononuclear cells using the *ApaI* polymorphism in exon 9 of the gene. A, IGF2 monoallelic expression. B, IGF2 biallelic expression. m, marker; g, genomic DNA; c, complementary DNA

---

*H.S. Kim, D.W. Lee, S.J. Lee, B.H. Choi, S.I. Chang, H.D. Yoon, I.K. Lee*
Figure 4. INS and IGF2 mRNA expression in mononuclear cells by RT-PCR.
A. Expression of the INS mRNA between ID32 and ID39.
B. Differences of the INS (191bp) and IGF2 (236bp) mRNA expression between ID32 and ID39.

DISCUSSION

Warram et al. (20) proposed that IDDM is transmitted to offspring by diabetic fathers more than twice as often as by diabetic mothers. This is the first indication that IDDM is related to parental imprinting. Following studies went on to examine the evidence of a linkage between IDDM transmission and parental imprinting (14, 21-24, 30, 32).

Of the families included in this study, 16 out of 42 were found to include type I diabetic members. Of these, 3 had a diabetic mother, although none had a diabetic father. These findings contrast with those from a previous report (20). We cannot explain the relationship between IDDM transmission and parental imprinting. INS and IGF2 are considered prime candidate genes for the IDDM2 locus and for IDDM2-encoded susceptibility (14, 21, 22, 24). This is especially true since IGF2 is exclusively expressed by the paternal copy in most tissues (33), which leads to our hypothesis that IDDM-encoded susceptibility is mediated by IGF2 (32). To test this, we examined genotype determination and allele-specific expression using mononuclear cells from IDDM patients and their parents. Twenty-nine of 40 type 1 diabetic patients express heterozygous and the data of parental genotype were available in only 9 of 29 type 1 diabetes patients. Only 3 cases of IGF2 mRNA revealed maternal origin. There seems to be polymorphic relaxation of IGF2 imprinting in leukocytes. But we need to require a much larger number of samples for statistical validity. However, these results are similar to the findings of previous reports that showed that IGF2 imprinting is relaxed in human peripheral lymphocytes (33-35). This relaxation was incomplete as maternal allele mRNA was systematically at a lower level than paternal. The paternal/maternal ratio varied widely among individual subjects. Variable relaxation of IGF2 imprinting seen in human leukocytes is not dependent on the presence of a class I versus a class III VNTR (36). Conclusively, mRNA from both IGF2 alleles was seen and it indicated relaxation of parental imprinting of IGF2 in leukocyte samples. Our results were not enough to evaluate the IGF2 imprinting effect but we could not exclude IGF2 as the candidate gene involved in IDDM2. However, the absence of an IGF2 imprinting effect suggests that, if there is a parental component in IDDM transmission, it is not mediated through IGF2. INS was shown to be imprinted in the yolk sac but not in the pancreas of mice (28). Maternal imprinting of the INS gene has originally been considered the most favorable explanation for the observed gender-related difference. However, previous studies demonstrated a biallelic expression of INS in pancreatic tissues with monoallelic and biallelic expression in the thymus of human fetuses. This suggests that INS is probably not imprinted in these tissues and is expressed tissue-specific pattern (36-40).

We studied the specific pattern of INS genotypes and the association of their allele-specific expression and INS imprinting in peripheral mononuclear cells from Korean type I diabetic patients. Thirty-six of the 37 IDDM patients were found to be PstI (+/+ ) and in 1 case, PstI (+/-). We could not demonstrate that the INS genotype was associated with parental imprinting in IDDM transmission because the majority of Koreans had PstI (+/+ ) INS genotypes. Also, there was no information about parental imprinting pattern of INS genotype in Asia because it had been difficult to get examples due to the same reason. This is the limitation to the study of INS genotype transmission in Korea. However, we can not exclude genetic and environmental differences between the patients of Korea and western countries, in which the occurrence of type 1 diabetes is found to be either rare or more common, respectively.

The RT-PCR assay of Bennett et al. (24) provides some evidence for a quantitatively different expression of the INS '+/' and '-' forms in the two heterozygotes. Bennett et al demonstrated 1.5 to 3-fold more expression of class I than class III haplotypes. We also measured the relationship between the genotypes and INS transcription
levels using semi-quantitative RT-PCR. Our findings were similar to Bennett et al.14 in that we found a 3-fold higher level of expression from PstI (+/-) with class III compared to PstI (+/+ ) with class III. However, Pagliaccio et al.7 observed that class III VNTR/PstI (-) mRNAs were transcribed at higher levels (2.5-fold on average) than class I VNTR/PstI (+) mRNA in the thymus and inverse correlation was found in pancreatic islet cell samples. VNTR alleles correlate with differential INS mRNA expression in the thymus where protective class III VNTRs are associated with higher steady-state levels of INS mRNA expression. This finding could explain the dominant protective effect of class III VNTRs because the elevated level of proinsulin in the thymus enhances negative allele-specific expression need to be conducted in a larger population of type I diabetic patients. Further study needed to conclusively confirm and define the association between INS transcription levels and IDDM parental transmission. Then, we may be able to better confirm parental genomic imprinting of IDDM transmission in the Korean type I diabetic population.

REFERENCES

1. Hall JG. Genomic imprinting: Review and relevance to human diseases. Am J Hum Genet 46:857-873, 1990
2. Sapienza C. Genomic imprinting: An Overview. Dev Genet 17:185-187, 1995
3. Sapienza C. Genomic imprinting: An Overview. Dev Genet 17:185-187, 1995
4. John RM. Surani MA. Imprinted genes and regulation of gene expression by epigenetic inheritance. Curr Opin Cell Biol 8:348-353, 1996
5. Hoffman AR, Vu TH. Genomic imprinting. Sci Am 52:61-61, 1996
6. Reik W, Surani MA. Genomic imprinting and embryonal tumors. Nature 338:112-113, 1989
7. Nichols RD, Knol JHM, Butcher MG, Karam S, Lalande M. Genetic imprinting suggested by maternal heterodisomy in nondelletion Parder-Willi syndrome. Nature 342:281-285, 1989.
8. Bach JF. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr Rev 15:6-154, 1994
9. Todd JA, Farnell M. Panning for gold: genome-wide scanning for linkage in type 1 diabetes. Hum Mol Genet 5:1443-1448, 1996
10. Fehi LL, Tobias R. Unraveling a complex trait: the genetics of insulin-dependent diabetes mellitus. Curr Med 20:40-49, 1997
11. Rach N. Assessing the role of HLA-linked and unlinked determinants of disease. Am J Hum Genet 40:1-18, 1987
12. Davies JL, Yoshikawa K, Bennett S, Copeman J B, Cordell HF, Pritchard LE, Reed PW, Gough SCI, Jenkens SC. A genome-wide search for human type 1 diabetes susceptibility genes. Nature 371:130-136, 1994
13. Bell GL, Horta S, Karam JH. A polyomavirus locus near the human insulin gene is associated with insulin-dependent diabetes mellitus. Diabetes 33:276-283, 1994
14. Julier C, Hoyer N, Davies J, Merlin F, Soubrane P, Brant L, Cathelineau G, Deschamps I, Rotter JI, Froogel P, Botard C, Bell JL, Lathrop GM. Insulin-RF2 region on chromosome 1p encodes a gene implicated in HLA-DR4-dependent diabetes susceptibility. Nature 354:255-258, 1991
15. Bain SC, Prins JB, Hearne CM, Rodrigues NR, Rowe BR, Pritchard LE, Richey JH, Hall JR, Undlien DE, Ronningen KS, Denger DB, Barnett AH, Todd JA. Insulin gene region-encoded susceptibility to type 1 diabetes is not restricted to HLA-DR4-positive individuals. Nat Genet 2:212-215, 1992
16. Lucassen AM, Julier C, Bessis JP, Botard C, Froogel P, Lathrop M, Bell J. Susceptibility to insulin dependent diabetes mellitus maps to a 4.4kb segment of DNA spanning the insulin gene and associated VNTR. Nat Genet 4:305-310, 1994
17. Overbach D, Gabbay KH. Localization of a type 1 diabetes susceptibility locus to the variable tandem repeat region flanking the insulin gene. Diabetes 42:708-714, 1993
18. She JX, Bui MM, Tian XH, Mair A, Welsh A, Zvonovich B, Zhang LP, Liu MC, Thomson G, Muenchen NK. Additive susceptibility to insulin-dependent diabetes conferred by HLA-DQB1 and insulin genes. Autoimmunity 8:95-102, 1994
19. Copeman JB, Cucca F, Hearne CM, Cornall RJ, Reed PW, Ronningen KS, Undlien DE, Nascito L, Buzzetti R, Tosi R, Pociot F, Nenup J, Cornelas F, Barnett AH, Bain SC, Todd JA. Linkage disequilibrium mapping of a type 1 diabetes susceptibility gene (IDDM7) to chromosome 2q31-3q33. Nat Genet 9:80-85, 1994
20. Warram JH, Knockowski AS, Gottlieb MS, Kahn CR. Differences in risk of insulin-dependent diabetes in offspring of diabetic mothers and diabetic fathers. N Engl J Med 331:85-852, 1994
21. Bui MM, Mair A, MacLaren NK, She JX. Linkage of the insulin gene with insulin-dependent diabetes in Caucasians suggest a maternal imprinting effect. Diabetes 42:63A, 1993

22. Pugliese A, Awdeh ZL, Apert CA, Jackson RA, Eisenbarth GS. The paternally inherited insulin gene B allele (1428 Fok I site) confers protection from insulin-dependent diabetes in families. J Autoimmunity 7:687-694, 1994

23. Polychronakos C, Kakolyris A, Giannoukakis N, Colle E. Parental imprinting effect at the INS-IGF2 diabetes susceptibility locus. Diabetologia 38:715-719, 1995

24. Bennett ST, Lucassen AM, Gough SCL, Powell EE, Undlien DE, Priorde LE, Mirmiran ME, Kawaguchi Y, Domsfield ML, Pociot F, Nenup J, Bouzekri N, Ronningen KS, Barnett AH, Bain SC, Todd JA. Susceptibility to human type 1 diabetes at IDDM is determined by tandem repeat variation at the insulin gene minisatellite locus. Nat Genet 9:284-292, 1995

25. Lucassen AN, Screaton GR, Julier C, Elliott TJ, Lathrop M, Bell JI. Regulation of insulin gene expression by the IDDM associated, insulin local haplotype. Hum Mol Genet 4:501-506, 1995

26. Owerbach D, Gabbay KH. The search for IDDM susceptibility genes: the next generation. Diabetes 45:544-551, 1996

27. Kennedy GC, German MS, Rutter WJ. The minisatellite in the diabetes susceptibility locus IDDM2 regulates insulin transcription. Nat Genet 9:293-297, 1995

28. Giddings SJ, King CD, Harman KW, Flood FF, Carnaghi L. Allele specific inactivation of insulin 1 and 2, in the mouse yolk sac, indicates imprinting. Nat Genet 6:310-313, 1994

29. DiChiara TM, Robertson EJ. Parental imprinting of the mouse insulin-like growth factor II gene. Cell 64:849-859, 1991

30. Giannoukakis N, Deal C, Paquette J, Goodyer CG, Polychronakos C. Parental genomic imprinting of the human IG2 gene. Nat Genet 4:98-101, 1993

31. Polychronakos C, Giannoukakis N, Deal C. Parental genomic imprinting of the human IG2 gene among individuals, in blood cells. Parental imprinting of the insulin gene in human pancreas. Biochem Biophys Res Commun 220:1014-1019, 1996

32. Polychronakos C, Giannoukakis N, Deal C. Imprinting of IG2. Insulin dependent diabetes, immune function, and apoptosis: A hypothesis. Dev Genet 15:253-262, 1995

33. Ward A, Bates P, Fisher R, Richardson L, Graham CF. Disproportionate growth in mice with IG2 transgenes. Proc Natl Acad Sci USA 91:10365-10369, 1994

34. Thompson MA, Cox Al, Whitehead RH, Jonas HA. Autoimmune regulation of human tumor cell proliferation by insulin-like growth factor II: an in vitro model. Endocrinology 126:3033-3042, 1990

35. Lucbello FC, Sewing A, Brussebach S, Berger C, Muller R. Deregulation of cyclin D1 and E and suppression of cdk2 and cdk4 in senescent human fibroblasts. J Cell Sci 105:123-133, 1993

36. Vafiadis P, Bennett ST, Colle E, Grabs R, Goodyer CG, Polychronakos C. Imprinted and genotype-specific expression of genes at the IDDM2 locus in pancreas and leukocytes. J Autoimmunity 9:97-103, 1996

37. Vafiadis P, Bennett ST, Todd JA, Grabs R, Polychronakos C. Divergence between genetic determinants of IG2 transcription levels in leukocytes and of IDDM2-encoded susceptibility to type 1 diabetes. J Clin Endocrinol Metab 83:2933-2939, 1998

38. Bui MM, Luo F, She JY, MacLaren NK, Mair A, Tomson G, She JX. Paternally transmitted IDDM2 influences diabetes susceptibility despite biallelic expression of the insulin gene in human pancreas. J Autoimmunity 9:97-103, 1996

39. Vafiadis P, Bennett ST, Todd JA, Nadeau J, Grabs R, Goodyer CG, Wickramasinghe S, Colle E, Polychronakos C. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nat Genet 15:289-292, 1997

40. Pugliese A, Zeller M, Fernandez A, Zakberg JJ, Bartlett RJ, Raci D, Pteropod M, Eisenbarth GS, Bennett ST, Patel DD. The insulin gene is transcribed in the human thymus and transcription levels correlate with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet 15:293-297, 1997